Table 3.
Associations between the MCT12 mutation and plasma and urinary creatine and guanidinoacetate by linear regression models
| Response Variable | Model 1 | Model 2 | Model 3 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| β | 95% CI | P Value | R2 | β | 95% CI | P Value | R2 | β | 95% CI | P Value | R2 | |
| Plasma creatine | −2.37 | (−13.82 to 9.08) | 0.67 | −0.04 | −3.90 | (−15.32 to 11.53) | 0.77 | <−0.004 | −6.03 | (−24.17 to 12.12) | 0.48 | −0.13 |
| Plasma guanidinoacetate | −1.04 | (−1.71 to −0.37) | 0.0042 | 0.34 | −1.19 | (−2.01 to −0.37) | 0.0074 | 0.30 | −1.66 | (−2.68 to −0.64) | 0.0041 | 0.38 |
| Creatine in 24-hour urine | 178 | (−97 to 104) | 0.19 | 0.04 | 220 | (−123 to 564) | 0.19 | −0.04 | 163 | (−315 to 640) | 0.47 | −0.22 |
| Guanidinoacetate in 24-hour urine | 134 | (−114 to 382) | 0.27 | 0.01 | 184 | (−130 to 499) | 0.23 | −0.03 | 130 | (−240 to 501) | 0.46 | 0.078 |
Model 1: univariate association. Model 2: adjusted for sex, age, and body mass index. Model 3: as Model 2 plus adjusted for cystatin C eGFR. The β coefficient of the prediction variable MCT12 mutation is indicated. MCT12 has the wild-type as reference group. The adjusted R-squared (R2) has been adjusted for all predictors in the model. Plasma creatine and guanidinoacetate are in μmol/l. Creatine and guanidinoacetate excretion in the 24-hour urine are in μmol/24 h. 95% CI, 95% confidence interval.